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•Upstream process development based on evaluation of: 
 temperature reduction
 supplementation with a productivity enhancer (valeric acid)
 perfusion operation
Aims of the work
• Enzyme used for replacement therapy of Gaucher disease (GD)
• In the market: imiglucerase (Cerezyme®), taliglucerase a, velaglucerase a
•Must be internalized into macrophages through mannose receptors
• Previous work at UFRJ (Brazil) developed GBA-producing clones from 
different CHO parental cell lines, including glycomutants*
Glucocerebrosidase (GBA)
*parental CHO glycomutants kindly provided by Pamela Stanley  (Albert Einstein College of Medicine, USA)
• Separate DOEs (22) for CHO-GBA-36K and CHO-GBA-65P clones 
• spinner flasks in batch mode
• customized CD, ADCF medium (TC-LECC, Xell AG)
Temperature and valeric acid addition
 Low temperature (31oC): 
beneficial for both clones
 Valeric acid supplementation: 
clone dependent effects
 Maximum qP: CHO-GBA-65P, 58.4 nU/cell/d
 4.2 fold higher than control at 37oC
 2.7 fold higher than maximum for 36K clone
CHO-GBA-65P
• CHO-GBA-65P clone
• Stirred-tank bioreactor with 
inclined settler
• Perfusion start on day 3
• Shift to 31oC on day 7
Biphasic perfusion
 Enzyme activity 
 9.5x higher than batch at 31oC
 22x higher than batch at 37oC
 Perfusion process at low T: 
higher volumetric productivity 
& higher titer  good for DSP
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